Improving Anti-Cancer Therapy by Reducing Dose Limiting Side Effects

Lutris Pharma is a clinical stage biopharmaceutical company established with a vision to improve anti cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) Inhibitors or with Radiation.

Dermal toxicity is the most prominent adverse reaction of EGFRi and radiation therapy, often limiting anti-cancer therapy compliance. Lutris provides novel topical therapies that significantly mitigate these side effects and enable patients to adhere to effective cancer treatments.